RSS   Newsletter   Contact   Advertise with us
Post Online Media

Innate Pharma names Mondher Mahjoubi as chairman of executive board

Mondher MahjoubiInnate Pharma SA, a clinical-stage biotechnology company, appoints Mondher Mahjoubi as chairman of its executive board, succeeding Hervé Brailly who becomes chairman of the supervisory board.
Article continues below

READ MORE MedDay names Catherine Moukheibir as chairman of its board

Dr. Mahjoubi is currently Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy, at AstraZeneca. He has been instrumental in driving the oncology strategy at AstraZeneca and beforehand at Genentech.

Dr. Mahjoubi is a medical oncologist trained at Institut Gustave Roussy (Paris-Villejuif).

He is bringing more than 20 years of experience working in clinical development, marketing and strategy in Europe and the USA for leading pharmaceutical companies in the field of oncology such as Aventis, Sanofi, Roche-Genentech, and AstraZeneca.

Dr. Brailly, who co-founded Innate Pharma 17 years ago, joins the Supervisory Board and will become its Chairman, succeeding Gilles Brisson who is stepping down after nine years in that position, and remains on the Board.

Dr. Philippe Pouletty, the longest serving member of the Board, will resign from the Board.

As part of the governance changes, Laure-Hélène Mercier has been appointed as Chief Financial Officer.

Ms. Mercier was previously EVP, Finance, in charge of financial operations and, before that, Head of Investor Relations.

Catherine Moukheibir, who has played a critical role as Senior Advisor for financial strategy, is leaving the Executive Board but will maintain her close links with the Company in an advisory position.

The leadership team and board changes will take effect on December 30th, 2016.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy